Company news

Oric Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ORIC Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update

November 7, 2021

ORIC Pharmaceuticals to Present Update on CD73 Inhibitor Program in Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting

November 3, 2021

ORIC Pharmaceuticals Presents Initial Clinical Data from Phase 1b Trial of ORIC-101 in Combination with Enzalutamide and Preclinical Data on ORIC-114 at AACR-NCI-EORTC

October 6, 2021

ORIC Pharmaceuticals Announces Multiple Data Presentations at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

September 29, 2021

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

September 20, 2021

ORIC Pharmaceuticals Appoints Steven L. Hoerter to its Board of Directors

August 15, 2021

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

August 9, 2021

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

June 27, 2021

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

June 1, 2021

ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

May 25, 2021

ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel

May 24, 2021

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

May 5, 2021

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

April 27, 2021

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

April 11, 2021

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

March 22, 2021

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

March 9, 2021

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

January 10, 2021

ORIC Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

December 20, 2020

ORIC Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

November 16, 2020

ORIC Pharmaceuticals Announces Pricing of Upsized Public Offering

November 12, 2020

ORIC Pharmaceuticals Announces Proposed Public Offering of Common Stock

November 9, 2020

ORIC Pharmaceuticals Reports Third Quarter 2020 Financial and Operational Update

November 4, 2020

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

October 18, 2020

ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020

October 8, 2020

ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update

August 4, 2020

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics

August 4, 2020

ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call

August 2, 2020

ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II

June 21, 2020

ORIC Pharmaceuticals Appoints Lori Kunkel, M.D., to its Board of Directors

June 8, 2020

ORIC Pharmaceuticals Announces Five Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting II

May 26, 2020

ORIC Pharmaceuticals to Present at the Jefferies 2020 Global Healthcare Conference

May 25, 2020

ORIC Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results

May 19, 2020

ORIC Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 27, 2020

ORIC Pharmaceuticals Presents Preclinical Data on CD73 Inhibitor at the American Association for Cancer Research (AACR) Virtual Annual Meeting

April 26, 2020

← Newer news releases

Calls

Decks

The 5 newest of 12 decks. Every deck is listed under its year.